We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AbbVie agreed to buy Allergan in June, offering $188 per share, or a 45% premium to the company's shares at the time. It was a price and a deal that analysts assessed as a boon for Allergan shareholders.